A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00670553

Enrollment

Registered

2008-05-02

Start date

2008-09-30

Completion date

2010-01-31

Last updated

2017-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer, Head & Neck Cancer, Prostate Cancer

Keywords

Prostate,, Head & Neck,, Esophageal

Brief summary

The purpose of this study is to assess the feasibility of combined administration of different LBH589 dosages with radiotherapy in order to establish the dosage to be evaluated in future studies.

Interventions

DRUGpanobinostat

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with age ≥18 years * Confirmed diagnosis of prostate cancer, SCC esophageal cancer or head & neck cancer * No evidence of distant spread of the disease

Exclusion criteria

* Patients who have severe and/or uncontrolled medical conditions * Female patients who are pregnant or breast feeding Other protocol-defined inclusion/

Design outcomes

Primary

Measure	Time frame
Establish Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD)	1 to 28 days

Secondary

Measure	Time frame
Safety profile of oral LBH589 when given in combination with standard Radiotherapy	min 1 month

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026